# VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)

> **NCT01249664** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 122 (actual)

## Conditions studied

- Myopia, Pathological

## Interventions

- **BIOLOGICAL:** VEGF Trap-Eye (BAY86-5321)
- **PROCEDURE:** No Drug

## Key facts

- **NCT ID:** NCT01249664
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-02
- **Final completion:** 2013-08
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2014-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01249664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01249664, "VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01249664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*